Oncocyte (NSDQ:OCX) announced yesterday that it entered into a development and co-marketing agreement with Thermo Fisher Scientific (NYSE:TMO). The development and co-marketing agreement covers two distributed in vitro diagnostic (IVD) assays on Thermo Fisher’s Ion Torrent Genexus system and grants Oncocyte the rights to develop future companion diagnostics on the Genexus system. Under the collaboration […]
OncoCyte
Oncocyte acquires Chronix Biomedical
Oncocyte (NSDQ:OCX) announced today that it completed its acquisition of molecular diagnostics company Chronix Biomedical. Irvine, Calif.-based Oncocyte’s acquisition includes the intellectual property and technology for Chronix’s TheraSure copy number instability (CNI) monitor test for immune therapy monitoring, according to a news release. Oncocyte also gains organ transplant technology and the associated patent portfolio developed […]
OncoCyte announces $7.6m offering
Molecular diagnostics company OncoCyte (NYSE:OCX) announced that two investors have agreed to purchase nearly $8 million of its common stock in a registered offering. Pura Vida Investments and another institutional investor combined for the $7.6 million offering, which was completed directly with the investors and included no placement agent fees. OncoCyte is slated to sell […]
